[go: up one dir, main page]

MX2015007169A - Uso de inhibidores de la telomerasa para el tratamiento de transtornos mieloproliferativos y neoplasias mieloproliferativas. - Google Patents

Uso de inhibidores de la telomerasa para el tratamiento de transtornos mieloproliferativos y neoplasias mieloproliferativas.

Info

Publication number
MX2015007169A
MX2015007169A MX2015007169A MX2015007169A MX2015007169A MX 2015007169 A MX2015007169 A MX 2015007169A MX 2015007169 A MX2015007169 A MX 2015007169A MX 2015007169 A MX2015007169 A MX 2015007169A MX 2015007169 A MX2015007169 A MX 2015007169A
Authority
MX
Mexico
Prior art keywords
myeloproliferative
telomerase inhibitors
treatment
neoplasias
myeloproliferative disorders
Prior art date
Application number
MX2015007169A
Other languages
English (en)
Other versions
MX372753B (es
Inventor
Monic J Stuart
Stephen Kelsey
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,711 external-priority patent/US9375485B2/en
Application filed by Geron Corp filed Critical Geron Corp
Publication of MX2015007169A publication Critical patent/MX2015007169A/es
Publication of MX372753B publication Critical patent/MX372753B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

En la presente se proporcionan métodos para reducir la proliferación de células progenitoras neoplásicas y aliviar los síntomas asociados en individuos diagnosticados con MPN o MDS o que se cree que tienen trastornos mieloproliferativos, tal como la trombocitopenia esencial (ET). En la presente también se proporcionan métodos para usar inhibidores de la telomerasa para mantener los conteos de plaquetas en la sangre en intervalos relativamente normales en la sangre de individuos diagnosticados o que se sospecha que tienen trastornos mieloproliferativos, tales como ET.
MX2015007169A 2012-12-07 2013-11-15 Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas. MX372753B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734941P 2012-12-07 2012-12-07
US201361799069P 2013-03-15 2013-03-15
US13/841,711 US9375485B2 (en) 2012-12-07 2013-03-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P 2013-11-05 2013-11-05
PCT/US2013/070437 WO2014088785A1 (en) 2012-12-07 2013-11-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Publications (2)

Publication Number Publication Date
MX2015007169A true MX2015007169A (es) 2016-03-31
MX372753B MX372753B (es) 2020-06-26

Family

ID=50883867

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015007169A MX372753B (es) 2012-12-07 2013-11-15 Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas.
MX2022015437A MX2022015437A (es) 2012-12-07 2015-06-05 Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas.
MX2020003276A MX2020003276A (es) 2012-12-07 2015-06-05 Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022015437A MX2022015437A (es) 2012-12-07 2015-06-05 Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas.
MX2020003276A MX2020003276A (es) 2012-12-07 2015-06-05 Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas.

Country Status (37)

Country Link
EP (3) EP3456333B8 (es)
JP (6) JP6433911B2 (es)
KR (4) KR102662590B1 (es)
CN (2) CN104936602B (es)
AP (1) AP2015008504A0 (es)
AU (4) AU2013356533B2 (es)
BR (1) BR112015013260A2 (es)
CA (2) CA3188494A1 (es)
CL (2) CL2015001530A1 (es)
CY (2) CY1122169T1 (es)
DK (3) DK3646876T3 (es)
EA (1) EA032973B1 (es)
ES (3) ES2789176T3 (es)
FI (2) FI3646876T3 (es)
FR (1) FR25C1016I1 (es)
HK (1) HK1210940A1 (es)
HR (3) HRP20240624T1 (es)
HU (4) HUE049858T2 (es)
IL (3) IL280144B2 (es)
LT (4) LT2928477T (es)
MA (2) MA45504B1 (es)
ME (1) ME03538B (es)
MX (3) MX372753B (es)
MY (2) MY180634A (es)
NL (1) NL301326I2 (es)
NZ (1) NZ708920A (es)
PH (2) PH12019501008A1 (es)
PL (3) PL3646876T3 (es)
PT (3) PT3646876T (es)
RS (2) RS59363B1 (es)
SG (3) SG10201802926XA (es)
SI (3) SI3456333T1 (es)
SM (2) SMT201900567T1 (es)
TN (1) TN2015000249A1 (es)
UA (3) UA128370C2 (es)
WO (1) WO2014088785A1 (es)
ZA (3) ZA201504124B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3296312T1 (sl) 2004-07-02 2021-08-31 Geron Corporation Sinteza zaščitenih 3'-amino 5'-fosforamiditnih nukleozidnih monomerov
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
RS60469B1 (sr) 2013-08-07 2020-07-31 Incyte Corp Dozni oblici sa produženim oslobađanjem za jak1 inhibitor
WO2015069758A1 (en) * 2013-11-06 2015-05-14 Ayalew Tefferi Methods and materials for treating hematological malignancies
JP2018513127A (ja) * 2015-04-23 2018-05-24 ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ 多価カチオン塩組成物を用いたポリヌクレオチド調製方法
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
AU2018307983B2 (en) 2017-07-28 2024-07-18 Geron Corporation Methods of treating myelodysplastic syndrome
IL319432A (en) 2018-04-30 2025-05-01 Kartos Therapeutics Inc Methods of treating cancer
JP2021525795A (ja) * 2018-05-25 2021-09-27 カルトス セラピューティクス，インコーポレイテッド 骨髄増殖性腫瘍を治療する方法
BR112021001204A2 (pt) * 2018-07-31 2021-04-27 Geron Corporation métodos de identificação de pacientes que provavelmente se beneficiarão do tratamento com um inibidor de telomerase
JP7650798B2 (ja) 2018-11-29 2025-03-25 ジェロン・コーポレーション 骨髄異形成症候群を治療する方法
JP7767279B2 (ja) 2019-11-04 2025-11-11 ジェロン・コーポレーション 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用
JP2021157248A (ja) * 2020-03-25 2021-10-07 パイオニア株式会社 状況出力装置
AU2021309963A1 (en) * 2020-07-17 2023-02-02 Geron Corporation Subcutaneous telomerase inhibitor compositions and methods for using same
WO2022159760A1 (en) * 2021-01-22 2022-07-28 The Regents Of The University Of California Methods for treating and ameliorating cancer
WO2024259369A1 (en) * 2023-06-14 2024-12-19 Rarecells Inc. Compositions targeting giant cells in blood disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
WO1998028442A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
AU2004209428A1 (en) * 2003-01-31 2004-08-19 Jessie L.-S. Au Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
CN1244592C (zh) * 2003-07-11 2006-03-08 暨南大学 抑制白血病细胞端粒酶活性的反义核酸及其应用
DK3342425T3 (da) 2003-09-09 2020-03-16 Geron Corp Modificerede oligonukleotider til inhibering af telomerase
US20050282893A1 (en) * 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
SI3296312T1 (sl) 2004-07-02 2021-08-31 Geron Corporation Sinteza zaščitenih 3'-amino 5'-fosforamiditnih nukleozidnih monomerov
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
US7998938B2 (en) 2005-04-15 2011-08-16 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2006113426A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
EP2898887B1 (en) * 2006-10-30 2018-09-26 Geron Corporation Combined telomerase inhibitor and gemcitabine for the treatment of cancer
CN101220044B (zh) * 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
EP2928477A4 (en) 2016-09-21
EP3456333B1 (en) 2020-04-01
SI3456333T1 (sl) 2020-10-30
PH12015501282A1 (en) 2015-08-24
KR20210107906A (ko) 2021-09-01
MY200076A (en) 2023-12-06
NL301326I2 (nl) 2025-07-31
FIC20250019I1 (fi) 2025-05-07
JP2016504307A (ja) 2016-02-12
PL3646876T3 (pl) 2024-07-22
UA117116C2 (uk) 2018-06-25
SMT201900567T1 (it) 2019-11-13
CA2892907A1 (en) 2014-06-12
EA201590878A1 (ru) 2016-04-29
ZA202108991B (en) 2023-05-31
AU2020267142C1 (en) 2024-08-08
TN2015000249A1 (en) 2016-10-03
NZ708920A (en) 2020-08-28
MA45504A1 (fr) 2020-05-29
MX372753B (es) 2020-06-26
CL2015001530A1 (es) 2016-03-28
JP2022179684A (ja) 2022-12-02
ZA202212327B (en) 2025-03-26
HRP20191784T1 (hr) 2019-12-27
EP3456333A1 (en) 2019-03-20
SI2928477T1 (sl) 2019-11-29
KR102662590B1 (ko) 2024-05-03
CN111617252A (zh) 2020-09-04
NZ748134A (en) 2020-10-30
ES2744790T3 (es) 2020-02-26
CN104936602B (zh) 2020-07-17
IL280144A (en) 2021-03-01
ES2982897T3 (es) 2024-10-18
ZA201504124B (en) 2017-05-31
RS60401B1 (sr) 2020-07-31
AP2015008504A0 (en) 2015-06-30
DK2928477T3 (da) 2019-10-07
EP3646876A1 (en) 2020-05-06
CA2892907C (en) 2023-03-21
DK3646876T3 (da) 2024-05-06
MA38193A1 (fr) 2017-12-29
PH12019501008A1 (en) 2022-11-14
MA38193B1 (fr) 2018-12-31
AU2013356533A1 (en) 2014-06-12
AU2013356533B2 (en) 2018-09-27
SMT202000328T1 (it) 2020-07-08
MX2020003276A (es) 2020-07-20
ES2789176T3 (es) 2020-10-26
EP2928477B1 (en) 2019-07-24
JP6998191B2 (ja) 2022-02-04
IL280144B1 (en) 2025-01-01
EP3456333B8 (en) 2020-05-13
PH12015501282B1 (en) 2015-08-24
HK1212226A1 (en) 2016-06-10
LT3646876T (lt) 2024-05-10
KR102294819B1 (ko) 2021-09-01
AU2024203138A1 (en) 2024-07-25
EP2928477A1 (en) 2015-10-14
JP6433911B2 (ja) 2018-12-05
EP3646876B1 (en) 2024-02-14
AU2020267142B2 (en) 2024-05-16
SG10202103341SA (en) 2021-05-28
IL239266A0 (en) 2015-07-30
BR112015013260A2 (pt) 2018-02-06
LTPA2025517I1 (es) 2025-05-26
KR20150091130A (ko) 2015-08-07
FR25C1016I1 (fr) 2025-06-20
IL280144B2 (en) 2025-05-01
HUE049858T2 (hu) 2020-11-30
LT3456333T (lt) 2020-06-25
RS59363B1 (sr) 2019-11-29
KR20250114449A (ko) 2025-07-29
CN104936602A (zh) 2015-09-23
HRP20240624T1 (hr) 2024-08-02
HK1210940A1 (zh) 2016-05-13
JP2022050537A (ja) 2022-03-30
SG11201504383TA (en) 2015-07-30
FI3646876T3 (fi) 2024-05-14
MX2022015437A (es) 2023-01-11
AU2020267142A1 (en) 2020-12-03
KR20230028590A (ko) 2023-02-28
CY1123206T1 (el) 2021-10-29
JP7288098B2 (ja) 2023-06-06
CL2017002156A1 (es) 2018-05-04
LT2928477T (lt) 2019-10-10
PT3646876T (pt) 2024-05-15
HUS2500019I1 (hu) 2025-05-28
ME03538B (me) 2020-07-20
MA45504B1 (fr) 2021-10-29
MY180634A (en) 2020-12-03
PT2928477T (pt) 2019-10-25
CA3188494A1 (en) 2014-06-12
UA126015C2 (uk) 2022-08-03
PT3456333T (pt) 2020-06-01
UA128370C2 (uk) 2024-06-26
JP2025109842A (ja) 2025-07-25
AU2018282364A1 (en) 2019-05-23
WO2014088785A8 (en) 2015-07-16
IL317233A (en) 2025-01-01
SI3646876T1 (sl) 2024-07-31
PL2928477T3 (pl) 2020-03-31
IL239266B (en) 2019-11-28
PL3456333T3 (pl) 2020-09-21
HUE066402T2 (hu) 2024-07-28
SG10201802926XA (en) 2018-05-30
JP2020041001A (ja) 2020-03-19
WO2014088785A1 (en) 2014-06-12
CY1122169T1 (el) 2020-11-25
JP2018035196A (ja) 2018-03-08
HRP20200993T1 (hr) 2020-11-27
HUE045098T2 (hu) 2019-12-30
DK3456333T3 (da) 2020-05-18
EA032973B1 (ru) 2019-08-30

Similar Documents

Publication Publication Date Title
MX2015007169A (es) Uso de inhibidores de la telomerasa para el tratamiento de transtornos mieloproliferativos y neoplasias mieloproliferativas.
GT201300215A (es) Inhibidores de glucosilceramida sintasa
GT201500051A (es) Inhibidores de glucosilceramida sintasa
AR092475A1 (es) Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r
GT201300128A (es) Variantes de fc silenciosas de los anticuerpos anti-cd40
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
MY185016A (en) Progenitor cells of mesodermal lineage
MX350588B (es) Composiciones de alcanos semifluorados.
ECSP11011436A (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS Y MÉTODOS DE USO
ECSP15026557A (es) Compuestos y sus métodos de empleo
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
IN2014DN06104A (es)
GT201300319A (es) Coagonistas del receptor de glucagón / glp-1
MX2020008031A (es) Composiciones y metodos para reducir el contenido de alcohol en sangre.
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
MX2014011583A (es) Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
EA201490562A1 (ru) Способы лечения связанной с инсультом сенсорно-двигательной недостаточности с использованием аминопиридинов
MX2015001695A (es) Regimenes de tratamiento.
AR082436A1 (es) Uso de teriflunomida para tratar la esclerosis multiple
EA201990799A1 (ru) Использование ингибиторов теломеразы для лечения миелопролиферативных нарушений и миелопролиферативных неоплазм
EA201792475A1 (ru) Клетки-предшественники мезодермальной линии
UA112059C2 (uk) Комбінована терапія із кріохірургією і іміквімодом для лікування актинічного кератозу (варіанти)
UY34069A (es) Semuloparina para la prevención de tromboembolismo venoso en pacientes con cáncer que están recibiendo quimioterapia

Legal Events

Date Code Title Description
FG Grant or registration